摘要:
The disclosure relates to in vivo and ex vivo uses of dihydronicotinamide riboside (NRH), dihydronicotinic acid riboside (NARH) and reduced derivatives thereof to treat immune-related disorders (e.g., systemic inflammatory response syndrome and sepsis), kidney disorders (e.g., acute kidney injury and hepatorenal syndrome [HRS]), liver disorders (e.g., acute liver failure and HRS), hemolytic disorders (e.g., hemolysis and hemolytic anemia), and disorders and conditions associated with oxidative stress, damage or injury (e.g., methemoglobinemia and anemia). NRH, NARH and reduced derivatives thereof can be used in vivo or ex vivo alone or in combination with one or more additional therapeutic agents, such as an anti-inflammatory agent or/and an antioxidant.
摘要:
Provided herein is a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme, wherein LG, A, n, m and p are as defined in the Summary of the Invention, said manufacture including the manufacture and use of a compound of the formula VI, wherein R1 is a secondary amino protecting group and R5 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted aryl.
摘要:
The invention discloses a method for preparation of alkylated or fluoro, chloro and fluorochloro alkylated compounds by a heterogeneous Pt/C-catalyzed alkylation or fluoro, chloro and fluorochloro alkylation with alkyl halides or with fluoro, chloro and fluorochloro alkyl halides in the presence of Cs 2 C0 3 or CsHC0 3 .
摘要翻译:本发明公开了在Cs 2 CO 3存在下,用烷基卤化物或氟,氯和氟氯代烷基卤化物进行异构Pt / C催化烷基化或氟,氯和氟氯烷基化制备烷基化或氟,氯和氟氯烷基化合物的方法 或CsHC03。
摘要:
The present invention relates to compounds which are of use in the field of agriculture as fungicides. The compounds are derivatives of succinate dehydrogenase inhibitors (SDHIs) which comprise different linker groups in place of the SDHI central amide. The invention also relates to uses, methods of use and compositions comprising said SDHI derivatives.
摘要:
The description relates to a pyridyl compound of Formula 1 wherein A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and n are as defined in the specification, in all their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, their pharmaceutically acceptable salts, N-oxides, pharmaceutically acceptable solvates, isosteres and prodrugs thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. The description also relates to a process for the manufacture of the pyridyl compound and a pharmaceutical composition containing the pyridyl compound.